White Paper

Meeting The Process Development Challenges Of A Diverse Biologic Pipeline

Source: Cytiva

By Mats Lundgren, Cytiva

GE_hyclone_dunker

How to navigate the evolving biopharmaceutical landscape from a process development standpoint

The biopharmaceutical industry has been growing and evolving at a pace that’s hard to match, especially in terms of manufacturing. Gone are the days when developers looked at monoclonal antibodies (mAbs), or antibodies that are made by identical immune cells cloned from a single cell, as a challenge – rather, mAbs have become an industry standard, with well-established research, development, and manufacturing processes that have proven to be robust and scalable. In the current biopharmaceutical landscape, developers are constantly encountering new and diverse biological molecules with complex structures. While these novel biologics are filling drug pipelines, they are also challenging existing manufacturing processes, both in upstream, downstream and analytical development.

Understanding what challenges these diverse molecules can create and how to manage these challenges is key to ensuring they reach patients safely and efficiently.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: